A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe

Clinical Therapeutics

Volumn 23, Issue 6, 2001, Pages 871-885

  Ezzet, Farkad ^a   Krishna, Gopal ^a   Wexler, David B ^a   Statkevich, Paul ^a   Kosoglou, Teddy ^a   Batra, Vijay K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol absorption inhibitor; Enterohepatic recycling; Ezetimibe; Population pharmacokinetics

Indexed keywords

EZETIMIBE; S PLUS;

ARTICLE; BILE SECRETION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG GLUCURONIDATION; ENTEROHEPATIC CIRCULATION; FOOD INTAKE; GALLBLADDER; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; MAJOR CLINICAL STUDY;

EID: 0034985134     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80075-8     Document Type: Article

References (28)

1. Hypercholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
2. SCH 48461, a novel inhibitor of cholesterol absorption
3. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
4. Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4-hydroxyphenyl)-2-azetidinone (SCH 58235): A designed, potent, orally active inhibitor of cholesterol absorption
5. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): Pooled analysis of two phase II studies
6. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption, in 243 hypercholesterolemic subjects: Results of a dose-response study
7. Ezetimibe. Hypolipidemic, cholesterol absorption inhibitor
8. Novel approaches to lipid lowering: What is on the horizon?
9. Novel lipid-regulating drugs
10. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
11. Pharmacokinetics and bioavailability of cimetidine in humans
12. Estimation of area under the curve for drugs subject to enterohepatic cycling
13. Use of SPICE, an electrical circuit analysis program, to simulate the occurrence of double peaks and evaluate critical factors in plasma concentration-time profiles after oral drug administration
14. Drug recirculation model with multiple cycles occurring at unequal time intervals
15. Enterohepatic recirculation of the new antihypertensive drug UP 269-6 in humans
16. Effect of food on oral bioavailability of SCH 58235 in healthy male volunteers
17. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor
18. Effect of age on the pharmacokinetics of ezetimibe
19. Estimation of population characteristics of pharmacokinetic parameters for routine clinical data
20. The effect of bile secretion on the pharmacokinetics of a theophylline sustained-release preparation
21. Nonlinear mixed effects models for repeated measures data
22. Metabolism of SCH 58235 in the human, rat and dog